ArticleBMC women's health2026
Molecular characteristics of follicular fluid in advanced maternal age women with different ovarian reserves: a multi-omics study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Follicular Immune Checkpoint: PD-1/PD-L1 and Immune Tolerance in Oocyte Competence and IVF Failure.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAge-related diminished ovarian reserve (DOR) exhibits marked significant individual variation. Some women of advanced age with normal ovarian reserve (NOR) achieve better reproductive outcomes than age-matched DOR patients.
objectiveThis study aimed to compare the metabolomic and proteomic profiles of follicular fluid (FF) from advanced maternal age(AMA) women with DOR and NOR, to reveal differences in the follicular microenvironment and identify potential biomarkers and related pathways.
methodsLC-MS/MS was employed to profile metabolites and proteins in FF samples from both groups. Differentially expressed metabolites (DEMs) and differentially expressed proteins (DEPs) were identified using multivariate and univariate statistical analyses. Functional annotation and pathway enrichment analyses were performed using the GO and KEGG databases. Metabolomic and proteomic data were analyzed using bioinformatic approaches to identify key molecules and potential biomarkers associated with DOR.
resultsUntargeted metabolomic analysis identified a total of 89 DEMs, including 32 upregulated and 57 downregulated. Data-independent acquisition (DIA) quantitative proteomic analysis identified 335 DEPs, of which 40 were up-regulated and 295 were down-regulated. Multi-omics analysis revealed significant alterations in several pathways in DOR patients, including metabolic pathways, cholesterol metabolism, alanine, aspartate and glutamate metabolism, carbon metabolism, central carbon metabolism in cancer, and sulfur metabolism. Based on protein expression profiles associated with these dysregulated pathways, four candidate protein biomarkers were further identified.
conclusionsBased on proteomic and metabolomic analyses, this study systematically characterized the follicular microenvironment of AMA with different ovarian reserve. A series of key DEPs and DEMs were identified, along with potential biomarkers of clinical relevance. Among the altered pathways, alanine, aspartate and glutamate metabolism may play an important role in the development of DOR, providing new directions for further investigation into its molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.